Target intelligence / Profile preview

F-box only protein 30 (FBXO30)

Target
FBXO30
Molecular classification
E3 ubiquitin ligase, F-box protein family (specifically the Fbxs subclass), SCF (SKP1-CUL1-F-box protein) ubiquitin ligase complex component
01

Overview

F-box only protein 30 (FBXO30) is a member of the F-box protein family, defined by a ~40 amino acid F-box motif that enables assembly into the SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex[3][4][6]. As a substrate recognition component, FBXO30 directs the SCF complex to its specific targets for ubiquitination and subsequent proteasomal degradation. FBXO30 has established roles in modulating protein turnover—including degradation of retinoic acid receptor gamma (RARγ) and hypoxia-inducible factor 1-alpha (HIF-1α)—thereby impacting BMP signaling, cell division, neural development, and muscle atrophy following denervation[1][2][6]. In cancer biology, FBXO30 has been characterized as a tumor suppressor in clear cell renal cell carcinoma and is dysregulated in nasopharyngeal and prostate cancer. Additionally, its expression and function are implicated in the regulation of mitosis, chromosome segregation, and susceptibility to neural tube defects[1][2]. Most research supports FBXO30 as a protein of emerging interest in ubiquitin-mediated proteolysis and cellular homeostasis.

Other names
F-box protein 30FBXO30FBX30MGC21674Fbx30F-box domain proteinF-box only proteinhelicase 18
02

Mechanism of action

Drugs or molecules targeting FBXO30 would likely modulate degradation of its substrates via the ubiquitin-proteasome pathway, potentially influencing processes such as cell cycle, proliferation, differentiation, neural development, and tumorigenesis[1][2][6].

03

Biological functions

Ubiquitination (targeted protein degradation)Regulation of protein stabilityMuscle atrophy regulation after denervationRegulation of neural developmentRegulation of cellular proliferation and mitosis
04

Disease associations

Cancer (implicated as a tumor suppressor in clear cell renal cell carcinoma and associated with nasopharyngeal and prostate cancer)Neural tube defects (by regulating BMP signaling through RARγ degradation)Muscle wasting/atrophy
05

Safety considerations

As FBXO30 regulates cellular protein turnover (e.g., HIF-1α, RARγ), therapeutic targeting could potentially disrupt processes like apoptosis, hypoxic adaptation, neural development, or muscle maintenance, leading to side effects such as impaired development or muscle atrophy[1][2][6].
06

Biomarkers

Downregulation or hypermethylation of FBXO30 as a potential biomarker for clear cell renal cell carcinoma and prostate cancer[2].Association with nasopharyngeal carcinoma[3].

Beyond the preview

Go deeper on F-box only protein 30 (FBXO30).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on F-box only protein 30 (FBXO30).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call